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Serum hepcidin following autologous hematopoietic
cell transplantation: an illustration of the interplay
of iron status, erythropoiesis and inflammation
Hepcidin, the key hormone in iron homeostasis,1 is reg-
ulated by erythropoietic activity and hypoxia (negative
feedback),2 as well as iron stores (hepcidin induction by
iron) and inflammation (upregulation).1,3 Only a few publi-
cations have focused on hepcidin in the context of
hematopoietic cell transplantation (HCT).4-7 We hypothe-
sized that changes in erythropoietic activity (myelosup-
pression followed by engraftment) and iron parameters
(raised ferritin and transferrin saturation (TSAT)) following
conditioning and transplantation had an impact on hep-
cidin levels. 
One hundred and twenty-seven patients were included
in our randomized trial comparing no erythropoietic ther-
apy, darbepoetin alpha (DA) therapy (300 µg QOW from
Day 28 to Day 112 posttransplant) in the DA group and
DA (same DA schedule) + intravenous (iv) iron sucrose
(200 mg on Days 28, 42 and 56) in the DA + iron group,
following autologous HCT.8 From among these, we ran-
domly selected 15 patients in each group. Patients’ charac-
teristics are summarized in Table 1. Details about transfu-
sion thresholds, blood analyses and patient eligibility are
reported elsewhere.8 Erythropoietic activity was evaluated
by soluble transferrin receptor (sTfR). Serum hepcidin-25
was quantified on serum samples stored before condition-
ing and on Days 7, 14, 28, 60, 100 and 180 post transplant,
by weak cation exchange time-of-flight mass spectrome-
try.9 
Figure 1A shows serum hepcidin over time in the 3
groups. Before HCT, hepcidin values were 2.53±3.16
(mean ± standard deviation), 3.93±2.99 and 5.02±4.35
nmol/L in the control, DA and DA + iron groups, respec-
tively (NS). Hepcidin peaked seven days after HCT, fol-
lowed by a rapid decrease until Day 28. Thereafter, hep-
cidin levels in the control group remained stable, whereas
those in DA groups decreased rapidly until Day 60. This
decrease was better illustrated with hepcidin expressed as
a percentage of Day 28 value (before DA treatment)
(Figure 1B). From Day 60, hepcidin levels in the DA + iron
group increased again and surpassed those in the control
and DA groups on Day 100. Two-way analyses of variance
(ANOVA) confirmed the effect of treatment group (control
vs. DA vs. DA + iron groups) and posttransplant time on
hepcidin levels (P<0.001). Hepcidin levels prior to trans-
plantation and on Days 14 and 28 correlated with nearly
all subsequent ones except with Day-7 values (P<0.01). 
Figures 1C, 1D, 1E and 1F show the evolution over time
of ferritin, TSAT, sTfR and Hb, respectively. Two weeks
after HCT, ferritin peaked in the 3 groups, then decreased.
TSAT was highest on Day 7, then decreased until Day 28.
After DA initiation on Day 28, TSAT tended to increase in
the DA + iron group. STfR levels dropped on Day 7 due to
conditioning, followed by a sharp increase with engraft-
ment. After DA initiation, sTfR increased in both DA
groups, but levelled off in the control group. 
All hepcidin values except those on Day 7 correlated
with preceding, same day or subsequent ferritin levels; cor-
relations were strongest when examined in same day sam-
ples, as well as on Days 60 and 100 (r approx. 0.75,
P<0.0001). Otherwise, hepcidin weakly correlated with
TSAT (r between 0.32 and 0.65, P values ranging from 0.05
to <0.0001) and negatively with sTfR (on Days 60 and
100: r between -0.41 and -0.58, P<0.02) and reticulocytes
(only on Day 100, r=-0.42, P=0.004). Finally, no significant
correlations were observed between hepcidin and C-reac-
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Table 1. Patients’ characteristics.
                                                          Control group                DA group DA + iron group Reference values
N. of patients                                                        15                                     15 15
Age (mean ± SD)                                             54±10                               58±5 54±11
Sex (F/M; #)                                                         7/8                                   3/12 4/11
Diagnosis (#)
Multiple myeloma                                                 9                                       8 7
Hodgkin lymphoma                                               2                                       0 2
High-grade NHL                                                    3                                       5 4
Low-grade NHL                                                     1                                       2 2
Status at transplantation (#)
1st or 2nd complete remission                             6                                       7 8
1st or 2nd partial remission                                   5                                       4 6
Beyond 2nd partial remission                              3                                       3 0
Undetermined                                                       1                                       1 1
Conditioning regimen (#)
Melphalan 200 mg/m²                                           9                                       8 7
BEAM                                                                       4                                       3 4
Cy-TBI                                                                      2                                       3 4
Other                                                                       0                                       1 0
Pre-transplant values (mean ± SD)
Hemoglobin                                                     10.8±2.4                          12.0±1.9 11.2±1.6 12-17 g/dL
Ferritin                                                             601±563                          620±639 525±478 25-300 ng/mL*
Transferrin saturation                                 0.38±0.08                        0.32±0.06 0.32±0.06 0.20-0.45
sTfR                                                                4,122±1,130                    5,808±2,772 6,577±2,770 3,000-7,000 ng/mL
Serum hepcidin                                             2.53±3.16                        2.93±2.99 5.02±4.35 <0.5-15.6 nmol/L*
DA: darbepoetin alpha; SD: standard deviation; NHL: non-Hodgkin lymphoma; BEAM: BCNU, etoposide, cytarabine, melphalan; Cy: cyclophosphamide; TBI: total body irradia-
tion. *Depending on gender and pre- and post-menopausal status.
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tive protein (CRP), Hb, Hct, percentages of hypochromic
red cells and erythropoietin. In multiple linear regression,
we found that ferritin was the independent variable most
commonly associated with hepcidin from Day 14 to 180
(Table 2). Erythropoiesis (reticulocytes) was also an impor-
tant determinant of hepcidin on Days 7 and 100.
Interestingly, CRP had also an impact on hepcidin on Days
60 and 100.
Hepcidin is the key regulator of iron metabolism but has
been little investigated in the context of HCT.4-7 Hepcidin
peaked at Day 7 post transplant and then gradually
decreased in the following three weeks without returning
to pre-transplant levels.5 In another study,6 hepcidin levels
at 3-5 months post transplant remained unchanged com-
pared to (high) pre-transplant values. On the other hand,
hepcidin response to erythropoietin therapy has been
examined in healthy volunteers10 or chronic kidney dis-
ease10,11 in whom erythropoietin (EPO) elicited a rapid and
persistent drop in serum hepcidin levels. Therefore, we
decided to investigate the long-term kinetics of hepcidin
after HCT in a group of patients participating in a clinical
trial of post-transplant DA with and without intravenous
iron therapy.8 In our study, hepcidin levels prior to HCT
were not increased compared to healthy controls.9 This is
in agreement with a previous study7 and is explained by
the low transfusion rates in our lymphoma and myeloma
patients before transplantation, contrarily to other studies
investigating mostly polytransfused patients with acute
leukemia or myelodysplastic syndromes.4-6 We also identi-
fied a hepcidin peak one week after transplantation.
Whereas Kanda attributed this peak to inflammation
because of a concomitant elevation of serum IL-6 levels
(not measured in our study),5 and although CRP in our
study also peaked at Day 7 (data not shown), we did not
observe any correlation between hepcidin and CRP values.
Among factors associated with hepcidin regulation, ery-
thropoietic activity and iron status are essential.1,3,12 We also
identified erythropoiesis and iron as major determinants of
serum hepcidin levels. The Day-7 peak (Figure 1A) could
result from concomitant suppression of erythropoietic
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Figure 1. Temporal evolution of
mean hepcidin (absolute values
(A) and percentage of Day-28 val-
ues (B)), ferritin (C), transferrin sat-
uration (D), sTfR (E) and hemoglo-
bin (F) following transplantation in
the 3 groups. *Comparisons
between either the DA group (*in
red) or the DA + iron group (*in
green) and the control group,
P<0.05. **Comparisons between
the DA group and the DA + iron
group, P<0.05.
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activity and elevated serum ferritin levels (due mainly to
the drop in iron utilization from the bone marrow and
inflammatory complications) (Figure 1C). However, we
cannot exclude the possibility that ferritin increased
because of iron retention in hepatocytes and macrophages
following the hepcidin peak. The ensuing rapid hepcidin
drop appears to correspond to fast recovery of erythro-
poiesis, as illustrated by the quick TSAT normalization
(Figure 1D) and sTfR surge (Figure 1E), whereas serum fer-
ritin decreased much slower. This rapid hepcidin decline is
coherent with the week-long hepcidin suppression follow-
ing a single EPO injection observed by Ashby10 in healthy
volunteers. In addition, analyzing hepcidin relatively to its
Day-28 (pre-DA) value (Figure 1B) clearly showed that
patients receiving no DA had stable values while patients
receiving DA experienced a marked drop corresponding to
further stimulation of erythropoiesis, whereas TSAT and
ferritin evolution remained superimposable in the 3
groups. Obviously, our observations also support the
experimental evidence that suppression of hepcidin during
anemia requires erythropoietic activity.13
Hepcidin values showed significant correlations with all
preceding or subsequent values, suggesting that whatever
the changes in erythropoietic activity, hepcidin remained
under the influence of a less variable parameter, i.e. iron
stores. The most robust associations were found between
serum hepcidin and ferritin, whereas those with sTfR were
less consistent, but the correlations were stronger prior to
and away from the day of transplantation, when inflam-
matory complications had resolved and erythropoiesis
recovered. Moreover, in the DA + iron group, hepcidin
increased from Day 60 onwards (Figure 1B), in parallel to
the evolution of ferritin and TSAT.
In summary, the evolution of serum hepcidin prior to
and following autologous HCT in our study was deter-
mined by the levels of both erythropoietic activity and iron
stores, while the effect of inflammation was less apparent.  
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Table 2. Multiple linear regression of various parameters with hep-
cidin as the dependent variable at each time point after HCT (group,
Hb, sTfR, reticulocytes, ferritin, transferrin saturation (TSAT) and CRP
were included into the model).
Correlation
Before conditioning None
Day 7 Reticulocytes (P=0.021)
Day 14 Reticulocytes (P=0.008)
Ferritin (P=0.029)
Day 28 Ferritin (P<0.001)
Day 60 Ferritin (P<0.001)
CRP (P=0.003)
Day 100 Ferritin (P<0.001)
Reticulocytes (P=0.002)
CRP (P<0.001)
Group (P<0.01)
TSAT (P=0.011)
Day 180 Ferritin (P=0.023)
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